Thalidomide-NH-PEG2-COOH
≥98%
- Product Code: 106468
CAS:
2412056-45-0
| Molecular Weight: | 433.41 g./mol | Molecular Formula: | C₂₀H₂₃N₃O₈ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, dry, sealed |
Product Description:
Thalidomide-NH-PEG2-COOH is primarily utilized in the development of PROTACs (Proteolysis Targeting Chimeras), a cutting-edge approach in targeted protein degradation. This compound serves as a crucial linker component, connecting the thalidomide moiety, which binds to the E3 ubiquitin ligase cereblon, to a target protein ligand. The PEG2 spacer enhances solubility and flexibility, optimizing the molecule's ability to facilitate the ubiquitination and subsequent degradation of disease-causing proteins. Its application is particularly significant in cancer research, where it aids in the selective elimination of oncogenic proteins, offering a promising therapeutic strategy. Additionally, it is explored in the treatment of neurodegenerative diseases and other conditions driven by pathogenic protein accumulation.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.025 | 10-20 days | £651.37 |
+
-
|
Thalidomide-NH-PEG2-COOH
Thalidomide-NH-PEG2-COOH is primarily utilized in the development of PROTACs (Proteolysis Targeting Chimeras), a cutting-edge approach in targeted protein degradation. This compound serves as a crucial linker component, connecting the thalidomide moiety, which binds to the E3 ubiquitin ligase cereblon, to a target protein ligand. The PEG2 spacer enhances solubility and flexibility, optimizing the molecule's ability to facilitate the ubiquitination and subsequent degradation of disease-causing proteins. Its application is particularly significant in cancer research, where it aids in the selective elimination of oncogenic proteins, offering a promising therapeutic strategy. Additionally, it is explored in the treatment of neurodegenerative diseases and other conditions driven by pathogenic protein accumulation.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
£0.00
£0.00
Total :